Vascular BioSciences Announces Publication of “Assessment of microRNA and gene dysregulaton in pulmonary hypertension by endoarterial biopsy” in the Current Issue of Pulmonary Circulation

May 19, 2017

Goleta, CA., May 19, 2017 – Vascular BioSciences announces publication of “Assessment of microRNA and gene dysregulaton in pulmonary hypertension by endoarterial biopsy” in the current issue of Pulmonary Circulation, Volume 7, Number 2, April to June 2017, pp. 1-10 by Abraham Rothman, Humberto Restrepo, Valeri Sarukhanov, William N. Evans, Robert G. Wiencek Jr, Roy Williams, Nicole Hamburger, Kylie Anderson, Jasmine Balsara, and David Mann. This article details how an endoarterial biopsy offers potential experimental and clinical diagnostic value by successfully showing that a large number of miRNAs that control PH-associated genes, molecular pathways, and biological processes are dysregulated in a porcine shunt model of PH.

With growing evidence that a large number of miRNAs are dysregulated in PH, an effective clinical method to detect and analyze these changes is needed. Endoarterial biopsies provide a technique to obtain vascular biopsy samples safely and of adequate size and quality to preform studies in a patient with PH of any etiology or at any particular stage of their disease. The detection of stage‒ and disease‒specific variation in gene expression could be used to design individualized medical therapy.

Dr. Abraham Rothman, M.D., of the Children’s Heart Center, Nevada and Professor of Medicine at the University of Nevada School of Medicine and study first author states, “Measuring miRNA (and other molecular) changes directly in individual patients at specific stages of their disease process offers great promise for advancing knowledge of the molecular mechanisms and designing specific personalized therapy.”

Vascular BioSciences CEO and study co‒author David Mann, commented, “Endoarterial biopsy provides an innovative method to assess miRNA, gene, and other molecular regulation in normal and hypertensive pulmonary arteries at specific stages of the disease and opens a new window for precision therapy.”